AVAV INVESTOR DEADLINE: AeroVironment, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

AeroVironment (AVAV) is facing a securities class action covering claims of misleading disclosures tied to the U.S. Space Force’s SCAR program. The article cites stock drops of nearly 16% (May 2025) and over 17% (March 2, 2026) alongside a reported Q3 FY2026 operating loss of $179.0M vs. a $3.1M loss a year earlier, including a $151.3M goodwill impairment after a stop-work order and subsequent contract termination. Overall, the allegations center on underestimated competition risk and overstated prospects, contributing to significant negative market reaction around stop-work/recompete developments.

Analysis

The bigger issue is not the lawsuit wrapper; it is that the SCAR exposure looks like it was being capitalized as if it were sticky, high-margin program content when it may have been a contestable bridge contract. That matters because the market will likely re-rate AVAV on a lower forward revenue visibility profile, not on the one-time impairment. In defense tech, losing perceived exclusivity usually hits valuation twice: first on forecast cuts, then on multiple compression as investors price a weaker follow-on funnel.

Second-order winners are the vendors with adjacent space/ground-systems capability that can absorb pieces of a recompete if the government splits scope or broadens competition. That argues for relative support in larger primes and space-electronics names with established procurement relationships, while AVAV faces a harder path to restore credibility. The key question is whether the customer wants a true competitive reset; if yes, AVAV’s prior economics may have been an outlier rather than a baseline.

Near term, the lawsuit headline is mostly noise; the real catalysts are procurement timing, amended-contract language, and any management disclosure on replacement work over the next 1-3 months. Tail risk is another downgrade or impairment if the program is re-baselined more aggressively than expected. The contrarian view is that the tape may already discount a worst-case outcome, so absent fresh procurement pain, the setup is more about avoiding fresh longs than pressing an oversized short.

Key Decisions for Investors

• Use AVAV as a relative-value short versus XAR or ITA over the next 1-3 months; thesis is company-specific procurement reset rather than sector-wide defense weakness. Falsifier: any amended SCAR agreement that preserves economics or a faster-than-expected award timeline.
• If you need defense exposure, prefer LHX or RTX over AVAV into the recompete window; they are better positioned to capture any split-award or rebid work. This is a structural 6-18 month allocation call, not a catalyst trade.
• Buy a 3-6 month AVAV put spread only if implied vol remains below realized volatility after the next headline cycle; use it to express downside from a second impairment or failed recompete. Risk/reward is best into relief rallies, not immediately after the impairment event.
• Avoid adding fresh AVAV longs until the market gets either procurement clarity or a clean quarter showing space margins stabilizing; the stock is now more sensitive to guidance credibility than to the litigation itself.